Dynamics of plasma hepatitis B virus levels after highly active antiretroviral therapy in patients with HIV infection

Journal of Hepatology

Volumn 39, Issue 6, 2003, Pages 1028-1035

  Fang, Chi Tai ^a   Chen, Pei Jer ^a,b   Chen, Mao Yuan ^a   Hung, Chien Ching ^a   Chang, Shan Chwen ^a   Chang, An Lung ^c   Chen, Ding Shinn ^a,b  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c Taipei Venereal Dis Contr Inst   (Taiwan)

Author keywords

Hepatitis B; Highly active antiretroviral therapy; Human immunodeficiency virus infection; Lamivudine

Indexed keywords

ANTIRETROVIRUS AGENT; DEOXYCYTIDINE; DIDANOSINE; HEPATITIS B(E) ANTIGEN; INDINAVIR; LAMIVUDINE; SAQUINAVIR; STAVUDINE; VIRUS DNA; ZIDOVUDINE;

ADULT; ARTICLE; CONTROLLED STUDY; DNA DEGRADATION; DRUG EFFICACY; FOLLOW UP; HEPATITIS B VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PERSISTENT INFECTION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; VIREMIA; VIRUS INHIBITION;

EID: 84984538372     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8278(03)00416-1     Document Type: Article

References (40)

1. Martin-Carbonero L, Soriano V, Valencia E, Garcia-Samaniego J, Lopez M, Gonzalez-Lahoz J. Increasing impact of chronic viral hepatitis on hospital admissions and mortality among HIV-infected patients. AIDS Res Hum Retroviruses 2001;17:1467-1471.
2. Puoti M, Spinetti A, Ghezzi A, Donato F, Zaltron S, Putzolu V, et al. Mortality for liver disease in patients with HIV infection: a cohort study. J Acquir Immune Defic Syndr 2000;24:211-217.
3. Bica I, McGovern B, Dhar R, Stone D, McGowan K, Scheib R, Snydman DR. Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clin Infect Dis 2001;32:492-497.
4. Palella FJ, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998;338:853-860.
5. Mocroft A, Vella S, Benfield TL, Chiesi A, Miller V, Gargalianos P, et al. Changing patterns of mortality across Europe in patients infected with HIV-1. Lancet 1998;352:1725-1730.
6. Moore RD, Chaisson RE. Natural history of HIV infection in the era of combination antiretroviral therapy. AIDS 1999;13:1933-1942.
7. Rustgi VK, Hoofnagle JH, Gerin JL, Gelmann EP, Reichert CM, Cooper JN, Macher AM. Hepatitis B virus infection in the acquired immunodeficiency syndrome. Ann Intern Med 1984;101:795-797.
8. Hadler SC, Judson FN, O'Malley PM, Altman NL, Penley K, Buchbinder S, et al. Outcome of hepatitis B virus infection in homosexual men and its relation to prior human immunodeficiency virus infection. J Infect Dis 1991;163:454-459.
9. Chen DS. From hepatitis to hepatoma: Lessons from type B viral hepatitis. Science 1993;262:369-370.
10. Liaw YF, Tai DI, Chu CM, Chen TJ. The development of cirrhosis in patients with chronic type B hepatitis: a prospective study. Hepatology 1988;8:493-496.
11. Yang HI, Lu SN, Liaw YF, You SL, Sun CA, Wang LY, et al. Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med 2002;347:168-174.
12. Colin JF, Cazals-Hatem D, Loriot MA, Martinot-Peignoux M, Pham BN, Auperin A, et al. Influence of human immunodeficiency virus infection on chronic hepatitis B in homosexual men. Hepatology 1999;29:1306-1310.
13. Thio CL, Seaberg EC, Skolasky Jr R, Phair J, Visscher B, Munoz A, et al. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet 2002;360:1921-1926.
14. Benhamou Y, Katlama C, Lunel F, Coutellier A, Dohin E, Hamm N, et al. Effects of lamivudine on replication of hepatitis B virus in HIV-infected men. Ann Intern Med 1996;125:705-712.
15. Dore GJ, Cooper DA, Barrret C, Goh LE, Thakrar B, Atkins M. Dual efficacy of lamivudine treatment in human immunodeficiency virus/ hepatitis B-coinfected persons in a randomized, controlled study (CAESAR). J Infect Dis 1999;180:607-608.
16. Hoff J, Bani-Sadr F, Gassin M, Raffi F. Evaluation of chronic hepatitis B virus (HBV) infection in coinfected patients receiving lamivudine as a component of anti-human immunodeficiency virus regimens. Clin Infect Dis 2001;32:963-969.
17. Benhamou Y, Bochet M, Thibault V, Calvez V, Fievet MH, Vig P, et al. Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus: an open-label pilot study. Lancet 2001;358:718-723.
18. Delaugerre C, Marcelin AG, Thibault V, Peytavin G, Bombled T, Bochet MV, et al. Human immunodeficiency virus (HIV) Type 1 reverse transcriptase resistance mutations in hepatitis B virus (HBV)-HIV-coinfected patients treated for HBV chronic infection once daily with 10 milligrams of adefovir dipivoxil combined with lamivudine. Antimicrob Agents Chemother 2002;46:1586-1588.
19. Nelson M, Portsmouth S, Stebbing J, Atkins M, Barr A, Matthews G, et al. An open-label study of tenofovir in HIV-1 and Hepatitis B virus co-infected individuals. AIDS 2003;17:F7-F10.
20. Ristig MB, Crippin J, Aberg JA, Powderly WG, Lisker-Melman M, Kessels L, et al. Tenofovir disoproxil fumarate therapy for chronic hepatitis B in human immunodeficiency virus/hepatitis B virus-coinfected individuals for whom interferon-alpha and lamivudine therapy have failed. J Infect Dis 2002;186:1844-1847.
21. Wong DK, Yim C, Naylor CD, Chen E, Sherman M, Vas S, et al. Interferon alpha treatment of chronic hepatitis B: randomized trial in a predominantly homosexual male population. Gastroenterology 1995;108:165-171.
22. Di Martino V, Thevenot T, Colin JF, Boyer N, Martinot M, Degos F, et al. Influence of HIV infection on the response to interferon therapy and the long-term outcome of chronic hepatitis B. Gastroenterology 2002;123:1812-1822.
23. Gerken G, Gomes J, Lampertico P, Colombo M, Rothaar T, Trippler M, et al. Clinical evaluation and applications of the Amplicor HBV Monitor test, a quantitative HBV DNA PCR assay. J Virol Methods 1998;74:155-165.
24. Ranki M, Schatzl HM, Zachoval R, Uusi-Oukari M, Lehtovaara P. Quantitation of hepatitis B virus DNA over a wide range from serum for studying viral replicative activity in response to treatment and in recurrent infection. Hepatology 1995;21:1492-1499.
25. Centers for Disease Control and Prevention, Report of the NIH panel to define principles of therapy of HIV infection and guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Morb Mortal Wkly Rep 1998;47(RR5):1-41.
26. Centers for Disease Control, 1993 Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. Morb Mortal Wkly Rep 1992;41(RR17):1-19.
27. Lewin SR, Ribeiro RM, Walters T, Lau GK, Bowden S, Locarnini S, Perelson AS. Analysis of hepatitis B viral load decline under potent therapy: complex decay profiles observed. Hepatology 2001;34:1012-1020.
28. Pichoud C, Berby F, Stuyver L, Petit MA, Trepo C, Zoulim F. Persistence of viral replication after anti-HBe seroconversion during antiviral therapy for chronic hepatitis B. J Hepatol 2000;32:307-316.
29. Carr A, Cooper DA. Restoration of immunity to chronic hepatitis B infection in HIV-infected patient on protease inhibitor. Lancet 1997;349:995-996.
30. Velasco M, Moran A, Tellez JM. Resolution of chronic hepatitis B after ritonavir treatment in an HIV-infected patient. N Engl J Med 1999;340:1765-1766.
31. Benhamou Y, Bochet M, Thibault V, Di Martino V, Caumes E, Bricaire F, et al. Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients. Hepatology 1999;30:1302-1306.
32. Tsiang M, Rooney JF, Toole JJ, Gibbs CS. Biphasic clearance kinetics of hepatitis B virus from patients during adefovir dipivoxil therapy. Hepatology 1999;29:1863-1869.
33. Perelson AS, Essunger P, Cao Y, Vesanen M, Hurley A, Saksela K, et al. Decay characteristics of HIV-1-infected compartments during combination therapy. Nature 1997;387:188-191.
34. Hsia CC, Thorgeirsson SS, Tabor E. Expression of hepatitis B surface antigen and core antigens and transforming growth factor-alpha in 'oval cells' of the liver in patients with hepatocellular carcinoma. J Med Virol 1994;43:216-221.
35. Lowes KN, Brennan BA, Yeoh GC, Olynyk JK. Oval cell numbers in human chronic liver diseases are directly related to disease severity. Am J Pathol 1999;154:537-541.
36. Workgroup for the elaboration of recommendations on viral hepatitis in HIV-infected patients. Coinfection by HIV and hepatitis A, B and C virus in adult patients: Review and GESIDA/PNS recommendations, 2003. Available from URL: http://www.hivandhepatitis.com/pdf/HIVandhepatitiscom.pdf
37. Pillay D, Cane PA, Ratcliffe D, Atkins M, Cooper D. CAESAR coordinating committee. Evolution of lamivudine-resistant hepatitis B virus and HIV-1 in co-infected individuals: an analysis of the CAESAR study. AIDS 2000;14:1111-1116.
38. Wolters LM, Niesters HG, Hansen BE, van der Ende ME, Kroon FP, Richter C, et al. Development of hepatitis B virus resistance for lamivudine in chronic hepatitis B patients co-infected with the human immunodeficiency virus in a Dutch cohort. J Clin Virol 2002;24:173-181.
39. Benhamou Y, Bochet M, Thibault V, Calvez V, Fievet MH, Sullivan M, et al. Adefovir dipivoxil 10 mg suppresses HBV viral replication in HIV/HBV coinfected patients with lamivudine resistant HBV. Program & Abstracts: 9th CROI, Seattle; 2002. p. a123. abstract.
40. Chen DS, Hoyer BH, Nelson J, Purcell RH, Gerin JL. Detection and properties of hepatitis viral DNA in liver tissue from patients with hepatocellular carcinoma. Hepatology 1982;2:42S-46S.